Drugs / Sodium Iodine I-131
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05668962 Background | Mar 2023 → Mar 2025 overdue | thyroid gland follicular carcinoma, thyroid gland papillary carcinoma | Massachusetts General Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium Iodine I-131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05668962 ↗ |
| Known as | I-131 NaI | “I-131 NaI” NCT05668962 ↗ |
| Route | Oral | “I-131 NaI, oral, is a standard treatment for all types of follicular-derived thyroid cancers, except anaplastic thyroid cancer” NCT05668962 ↗ |